

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

2

Application Number

10/868,920

Filing Date

September 23, 2003

First Named Inventor

ARNAIZ et al.

Art Unit

1626

Examiner Name

CHUNG, Susannah Leo

Attorney Docket Number

52340AUSM1

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input checked="" type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	
	MAIL STOP: ISSUE FEE Technology Center: 1626	
	This correspondence is being facsimile transmitted to Mail Stop Issue fee at (571) 273-2885.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	BERLEX BIOSCIENCES		
Signature	<i>Jacqueline S. Larson</i>		
Printed name	JACQUELINE S. LARSON		
Date	Feb. 28, 2006	Reg. No.	30,279


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature	<i>M. Flores</i>		
Typed or printed name	MARY ANN FLORES	Date	2/28/06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Serial No. 10,668,920

PAGE 1
CASE 52340AUSM1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

:

Damian O. ARNAIZ et al.

Serial No. 10/668,920

: Group Art Unit 1626

Filed 09/23/2003

: Examiner CHUNG, Susannah Lee

For: Imidazolidinedione Analogs Useful as Anticoagulants and Antithrombotics


Mail Stop ISSUE FEE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

I hereby certify that this correspondence is being facsimile transmitted to mail stop Issue Fee at the USPTO at facsimile (571) 273-2865 on the date below.


Mary Ann Figgins2/28/06
Date of Signature

Sir:


**APPLICANTS' COMMENTS REGARDING THE
RESPONSE TO RULE 312 COMMUNICATION**

With regards to the Response to Rule 312 Communication, mailed 02/17/2006, Applicants have the following comments:

Applicants do not agree with the reasons for disapproval of the Rule 312 Amendment as set out in the Response. That is, Applicants do not agree that the claims filed on 12/20/2005 are not enabled or commensurate in scope with the allowed claims 3 and 9.

However, while Applicants do not agree with the stated reasons for non-entry of the claims, their undersigned representative agreed, during an interview with the Examiner on 02/09/2006, to withdraw the Rule 312 Amendment in order to expedite issuance of the present application to patent, with the proviso that the subject matter of the non-entered claims may be pursued in a continuing application.

Respectfully submitted,



Jacqueline S. Larson
Patent Attorney for Applicants
Registration No. 30279

Date: Feb. 28, 2006

Berlex Biosciences
Corporate Patents
P.O. Box 4099
Richmond, California 94804-0099
Telephone: (510)-669-4483
Fax: (510)-262-7095